Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male

Table 2

Demographics of previous and present cases of Guillain-Barré syndrome associated with COVID-19 in Japan.

Case	Age	Sex	Clinical feature	GBS onset from the onset of COVID-19	GBS onset from COVID-19 recovery	GBS electrophysiological subtype	Anti-ganglioside antibody	CSF protein (mg/dL)	Immunological treatment
Wada et al. [7]	69	Male	Absence of cough reflex, muscle weakness, areflexia	Not described	Not described	Not described	Anti-Gal-C antibody	202	IVIg
Hirayama et al. [5]	54	Female	Muscle weakness, numbness, and areflexia in the lower limb	20	Approximately 1 week	Axonal type	Negative	Normal level	No treatment
Kakumoto et al. [6]	22	Male	Muscle weakness, hypesthesia, dysarthria, dysphagia, left-sided facial numbness, and dysautonomia	16	6	AIDP	Negative	307	IVIg
Present case	52	Male	Muscle weakness, dysphagia, areflexia, hyperhidrosis	10	1	AIDP	Anti-GM3 antibody	55	IVIg, IVMP

Abbreviations: GBS, Guillain–Barré syndrome; CSF, cerebrospinal fluid; AIDP, acute inflammatory demyelinating polyneuropathy; IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone.